Compare HCA Health Inc (HCA) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? HCA Health Inc trades at $474.89 (market cap $99.75B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: HCA Health Inc is far larger — about 13.3× Spyre Therapeutics Inc. Common Stock's market cap, and HCA Health Inc pays a 0.68% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HCA | SYRE | |
|---|---|---|
Market Cap | $99.75B | $7.52B |
Volume | 1,083,231 | 1,441,031 |
Sector | Health | Health |
52-Week High | $545.13 | $108.92 |
52-Week Low | $361.32 | $22.18 |
Typical Hold Time | 76 Days | 0 Days |
Enterprise Value | $150.29B | $6.52B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare's stock trades at $470.44, up 2.58% today, with a bullish technical outlook and strong earnings beats in recent quarters. Revenue grew to $75.60B in 2025, with a net income margin of 8.77%, while the P/E ratio of 15.45 suggests reasonable valuation. Recent news includes an upcoming Q3 2026 earnings call and ongoing legal investigations, creating mixed sentiment.
The outlook is positive due to consistent earnings performance and analyst buy ratings, but risks include high debt levels and regulatory scrutiny. Investment opportunity lies in operational efficiency and demand growth, though investors should monitor legal developments and debt management.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
